GAIN FIRSTHAND INSIGHT FROM LEADERS IN GLOBAL MEDICINE

Wednesday September 11
Main stage: 09.00-09.20
Welcome
Dr. Patrice Matchaba, Group Head of Global Health and Corporate Responsibility, Novartis

Patrice Matchaba, M.D., has been Global Head of Corporate Responsibility for Novartissince October 1, 2017.

Dr. Matchaba most recently served as Global Head of the Cardio-Metabolic development unit at Novartis, where he led the global clinical development of the cardio-metabolic portfolio. He joined Novartis South Africa in 2000 as the Country Pharma Organization Chief Scientific Officer. Since moving to Novartis Pharmaceuticals Corporation in the United States in 2002, he has held several roles of increasing responsibility such as Therapeutic Area Head for Immunology and Infectious Diseases; Global Head of Drug Safety and Epidemiology; and Global Head of the Integrated Development Functions and Regions, which include Global Clinical Operations, Global Clinical Submissions, Integrated Information Sciences, Development Informatics, Development Diversity and Inclusion, and all Medical Country Pharma Organization regions.

Dr. Matchaba completed his medical training at the University of Zimbabwe, and is a fellow of the College of Obstetrics and Gynecology South Africa. In addition, he is a graduate of Harvard Business School’s Program for Management Development.

Wednesday September 11
Main stage: 10.10-10.35
AI in Pharma – promise, reality and challenges
Dr Shahram Ebadollahi, Global Head of Data Science and AI, Novartis

Dr. Shahram Ebadollahi is the Global Head of Data Science and AI at Novartis. In this capacity, he is responsible for defining and shaping the strategy for applications of data science across the pharmaceutical pipeline, from early discovery to manufacturing. He also oversees globally the execution of the strategy and operations of the data science and AI efforts and teams across Novartis.

Before joining Novartis in September of 2018, Dr. Ebadollahi spent 14 years with IBM and had a series of senior executive roles. He was the technical founder of IBM Watson Health, IBM’s first ever business focused on applications of technology and AI to the domain of healthcare and life sciences. In that role, he oversaw innovations, development, and served as the Chief Science Officer of IBM in the area of healthcare. Prior to starting IBM Watson Health, he had started the health informatics research and computational health, with the aim of innovating and applying data-driven and knowledge-driven advanced analytics to the broad domain of healthcare and life sciences. As the Vice President of Health Informatics Research, he oversaw a global team of scientists and innovators in this domain.
One of the latest innovations he started and oversaw before his departure from IBM was applications of blockchain technology to healthcare, which resulted in collaborations with the FDA, CDC and more recently the formation of the Health Utility Network between IBM and a number of health insurance companies and banks.

Dr. Ebadollahi has a PhD and MBA from Columbia University and is a member of a number of scientific and business advisory boards at the intersection of technology innovation, data science and novel business models with focus in the domain of healthcare and life sciences. He has published and overseen graduate level research in the area of analytics for healthcare and has conducted research with funding from national institutions such as NIH. He is a frequent speaker and panelist at events at the intersection of technology innovation and healthcare.

Wednesday September 11
Mainstage: 11.55-12.30

  Panel Discussion: Health systems managers, clinicians & policy maker’s perspective: How can AI transform healthcare
Dr Ann Aaerts, Head, Novartis Foundation 

Ann Aerts has been Head of the Novartis Foundation since January 2013, an organization committed to having a transformational impact on the health of low-income populations. Ann holds a Degree in Medicine and a Masters in Public Health from the University of Leuven, Belgium, and a Degree in Tropical Medicine from the Institute of Tropical Medicine in Antwerp, Belgium.

In 2014, Ann was nominated by PharmaVOICE as one of the 100 Most
Inspiring People in the life science industry. Ann has authored numerous publications and is a member of the Broadband Commission for Sustainable Development, the Governing Council of the UN Technology Bank for Least Developed Countries and the International Advisory Board of the Commonwealth Centre for Digital Health.

Wednesday September 11
Delhi Room: 14.00-15.30

  Workshop 1: Emerging use cases for AI in global health

Join the Novartis Foundation and partners to explore how AI can transform individual care, health system performance, population care and even R&D in low- and middle-income (LMIC) countries. Together, we will explore questions such as:

How can AI transform individual care in LMIC?

How can AI transform health system performance and processes in LMIC?

How can AI transform population care in LMIC?

What are the challenges and roadblocks that exist for AI in global health?

Dr Ann Aaerts, Head, Novartis Foundation 

Geoffrey So, Head of Strategy & Global Health Policy, Novartis Foundation 

Geoffrey So is the Head of Strategy & Global Health Policy at the Novartis Foundation. He works across the portfolio of global health initiatives and cultivates collaborations with traditional and non-traditional health partners with the aim to strengthen healthcare delivery and health systems, and generate data and evidence for policy change, integration and scale. He oversees the management of Better Hearts Better Cities, a multidisciplinary, multisector initiative to improve hypertension control and cardiovascular health in low-income urban communities in Brazil, Mongolia and Senegal.

Prior to joining the Novartis Foundation, Geoffrey worked at the United Nations and World Health Organization. In the Executive Office of the UN Secretary-General, he served as a global health advisor for Every Woman Every Child, and advocacy and communications lead for Amina J. Mohammed in the Post-2015 Sustainable Development Unit. At WHO/Roll Back Malaria Partnership, he was responsible for external relations with governments, businesses and civil society for malaria and resource mobilization efforts.

Geoffrey trained as a public health epidemiologist in Canada and his former research includes HIV and Hepatitis C harm reduction, influenza diagnostic tool optimization, and the prevention and treatment of cardio-metabolic diseases among HIV-positive individuals in Sub-Saharan Africa.

Ann Aerts has been Head of the Novartis Foundation since January 2013, an organization committed to having a transformational impact on the health of low-income populations. Ann holds a Degree in Medicine and a Masters in Public Health from the University of Leuven, Belgium, and a Degree in Tropical Medicine from the Institute of Tropical Medicine in Antwerp, Belgium.

In 2014, Ann was nominated by PharmaVOICE as one of the 100 Most Inspiring People in the life science industry. Ann has authored numerous publications and is a member of the Broadband Commission for Sustainable Development, the Governing Council of the UN Technology Bank for Least Developed Countries and the International Advisory Board of the Commonwealth Centre for Digital Health.

Thursday September 12
MCH Room: : 14.00-15.20

Startups Showcase – Judge

Peter Speyer, Head of Products, data42, Novartis

Peter Speyer is Head of Products, data42 at Novartis, responsible for implementing data and analytic products in a transformational program that leverages data from across R&D for machine learning and AI. Before data42, Peter led teams to develop platforms to collect, manage and analyze data as Head of Digital, Medical and Real World Evidence Solutions. Before Novartis, Peter was Chief Data & Technology Officer at the Institute for Health Metrics and Evaluation (IHME) at the University of Washington in Seattle. He was responsible for data and IT for high-profile analytic projects like the Global Burden of Disease (GBD) study, including obtaining and managing data from 190 countries, running high performance computing infrastructure, and creating IHME’s global public data catalog Global Health Data Exchange (GHDx) and innovative interactive data visualizations.
Prior to joining IHME, Peter worked in strategy and product management in the media industry, including Corbis and Bertelsmann. He holds an MBA from Temple University in Philadelphia, USA, and a Master in Business and Engineering from the Karlsruhe Institute of Technology, Germany.

Thursday September 12
Main stage: : 12.40-13.00

Keynote: AI in healthcare in low-income communities

Dr Ann Aaerts, Head, Novartis Foundation 

Thursday September 12
Main stage: : 14.00-16.30

Workshop 5

Artificial intelligence and digital health – an international platform to enable action

Dr Ann Aaerts, Head, Novartis Foundation 

During this 2 ½ hour consultation, convened by Ambassador Amandeep Singh Gill, Former Executive Director, UNSG High Level Panel on Digital Corporation, Fondation Botnar and the Novartis Foundation, we will come together to “ideate” on a number of key issues  – defining key terms and goals for digital health; outlining the critical financial, human resource and technical challenges to the global spread of digital and AI enablers for health; distilling priorities for research and evaluation; and listing cross- border gaps in governance, benchmarks and standards which would need to be addressed urgently so that AI and data can be deployed safely and securely for health. The results of this consultation will feed into the development of a new international collaboration on AI and health.

Ann Aerts has been Head of the Novartis Foundation since January 2013, an organization committed to having a transformational impact on the health of low-income populations. Ann holds a Degree in Medicine and a Masters in Public Health from the University of Leuven, Belgium, and a Degree in Tropical Medicine from the Institute of Tropical Medicine in Antwerp, Belgium.

In 2014, Ann was nominated by PharmaVOICE as one of the 100 Most Inspiring People in the life science industry. Ann has authored numerous publications and is a member of the Broadband Commission for Sustainable Development, the Governing Council of the UN Technology Bank for Least Developed Countries and the International Advisory Board of the Commonwealth Centre for Digital Health.